Introduction: Primary penile sarcoma has an incidence of 0.6 in 100,000 patients in developed countries. Risk factors such as radiotherapy have been identified, which can generate mutagenesis of the irradiated tissue adjacent to the irradiation field. Given the increase in survival of patients that received radiotherapy, the incidence of radio-induced sarcomas has increased. We report the first documented case in Latin America of radio-induced undifferentiated sarcoma of the penis. Materials and Methods:Case report and literature review. Results:We report the case of an 89 year-old male patient, who consulted due to a 9-month history of intermittent urethrorrhagia, penile pain and priapism. It is noteworthy that he received radiotherapy for prostate adenocarcinoma. Ultrasound and MRI of the pelvis confirmed a tumor dependent on the right corpus cavernosum, and it was decided to take a biopsy of the mass. Biopsy of the lesion showed a high-grade undifferentiated sarcoma. He underwent radiotherapy and surgery, he had an unfavorable evolution and died shortly after. Conclusion:Radio induced sarcomas of the penis are rare and usually have a poor prognosis due to delayed diagnosis. Its early diagnosis is difficult because the initial symptomatology is nonspecific, very similar, for example, to that of Peyronie's disease. Thus, a suspicion and timely identification can impact the prognosis of these neoplasms.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.